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1. Summary
The TGFb receptors signal through phosphorylation and nuclear translocation
of SMAD2/3. SMAD7, a transcriptional target of TGFb signals, negatively regu-
lates the TGFb pathway by recruiting E3 ubiquitin ligases and targeting TGFb
receptors for ubiquitin-mediated degradation. In this report, we identify a deubi-
quitylating enzyme USP11 as an interactor of SMAD7. USP11 enhances TGFb
signalling and can override the negative effects of SMAD7. USP11 interacts
with and deubiquitylatesthe type I TGFb receptor (ALK5), resulting in enhanced
TGFb-induced gene transcription. The deubiquitylase activity of USP11 is
required to enhance TGFb-induced gene transcription. RNAi-mediated depletion
of USP11 results in inhibition of TGFb-induced SMAD2/3 phosphorylation and
TGFb-mediatedtranscriptional responses.Centralto TGFbpathwaysignallingin
early embryogenesis and carcinogenesis is TGFb-induced epithelial to mesench-
ymal transition. USP11 depletion results in inhibition of TGFb-induced epithelial
to mesenchymal transition.
2. Introduction
The signalling pathways downstream of the transforming growth factor b
(TGFb) family of receptors play critical roles in regulating cellular proliferation,
apoptosis, differentiation and migration [1–3]. TGFb pathway aberrations have
been reported in a wide range of musculoskeletal, cardiovascular, reproduc-
tive and neurological pathologies both acquired and developmental [4].
Furthermore, malfunction of the TGFb pathway is associated with cancer and
metastasis, and the loss of TGFb cytostatic responsiveness is a characteristic
of many cancers [2,5]. Therefore, understanding TGFb pathway regulation
may present new opportunities for the development of novel target-specific
therapeutic interventions. While multiple articles have been published on the
subject, many gaps remain in our knowledge of TGFb pathway regulation,
especially after signalling has been initiated.
Signalling is initiated when TGFb ligands bind to their transmembrane
serine/threonine kinase cognate receptors. Ligand binding induces specific pair-
ingoftypeI(ALK1-7)andtypeII(ACVR-IIA,ACVR-IIB,BMPR-II,AMHR-IIand
TGFbR-II) receptors in a quaternary complex. Type II receptors phosphorylate
andactivatethetype I receptors. SMAD proteinsare the intracellularsignaltrans-
ducers of activated receptor complexes and are divided into three groups:
receptor-regulated(R-)SMADs(1–3,5and8),theco-SMAD(4)andtheinhibitory
(I-) SMADs (6 and 7). Once activated, type I receptors phosphorylate different
R-SMADs at their C-terminal SXS motif depending on the receptor pairing and
the ligand. This induces R-SMAD complex formation with SMAD4 and trans-
location to the nucleus, where along with other cofactors they regulate
transcription of more than 500 target genes. The I-SMADs are transcriptionally
& 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.induced by TGFb and bone morphogenic protein (BMP),
creating a negative feedback by targeting the receptors for
ubiquitin-mediated degradation and competing with
R-SMADs for association with the type I receptors [6,7]. The
TGFb subfamily of receptors signal through SMADs 2 and 3
and are inhibited by SMAD7, while the BMP subfamily signal
through SMADs 1, 5 and 8 and are inhibited by both SMADs
6 and 7. However, some crosstalk between the two pathways
has been reported [1,8].
Regulation of the TGFb pathway can occur at multiple
levels and by various molecular mechanisms. One of the
key modes of regulation is by reversible ubiquitylation
of the protein components driving the TGFb pathway.
Ubiquitin is a member of a conserved family of eukaryotic
proteins sharing the ubiquitin fold structure. Attached
through an isopeptide bond to lysine residues of target pro-
teins, they are used as modifiers of localization, stability
and activity. Additional ubiquitins can be attached to one
of the several lysine residues on the protein-bound ubiquitin,
creating polyubiquitin chains. Depending on the type of
polyubiquitin chains formed, different fates await the poly-
ubiquitylated protein. Although several chain types exist,
not all have been attributed a function. Of the commonly
studied, K48 chains are known to signal degradation,
whereas K63 chains play a role in signalling as well as protein
trafficking and endocytosis [9,10].
Ubiquitin attachment is achieved through a three-step
process using ubiquitin activating (E1) and conjugating (E2)
enzymes, as well as a wide array of (E3) ligases [9]. Specific
to the TGFb pathway, the E3 ubiquitin ligases SMURF1
and NEDD4L attenuate TGFb signalling by ubiquitylating
SMAD1 and SMAD2/3, respectively [11–15]. SMAD4 is
regulated by reversible ubiquitylation [16]. SMAD7 recruits
SMURF1/2, WWP1 and NEDD4L targeting the type I
receptors for ubiquitin-mediated degradation [7,17,18].
SMAD7 itself is a target for ubiquitylation by the E3 ligase
ARKADIA [19]. A further layer of control is exerted on the
pathway by editing or removing the ubiquitin chains from
targeted pathway members, therefore changing their fate
and localization. While the regulation of the TGFb pathway
by ubiquitylation has been extensively investigated and
reported, deubiquitylation has not [11]. Consequently, there
have been very few deubiquitylating enzymes (DUBs)
reported to act on the TGFb pathway [16,20–22].
There are at least 79 DUBs encoded in the human genome
that are responsible for editing and removing ubiquitin chains
by cleaving the isopeptide bond [23]. In this study, we intro-
duce USP11 as a DUB capable of regulating the TGFb
pathway. USP11 and 56 other USP proteins share the USP
domain; this contains the two or three amino acid residues
forming the catalytic diad or triad required to cleave ubiquitin
chains. They diverge structurally with various regulatory, ubi-
quitin binding and protein binding domains directing them to
different targets. USP11 has been described to be involved in
other pathways. It has been shown to associate with:
RanBPM in the nucleation of microtubules, IkBa in the TNFa
pathway, BRCA2 in DNA repair and HPV-16E7 enhancing
HPV virus replication in relation to cervical cancer while inhi-
biting influenza virus replication. These functions among
others have been reported to be both dependent and indepen-
dent of its DUB activity [24–30]. Here, we report USP11 as a
TGFb pathway DUB capable of modulating TGFb-induced
signalling and downstream cellular functions.
3. Results
3.1. Identification of USP11 as an interactor of
GFP-SMAD7
In order to uncover molecular mechanisms by which SMAD7
regulates the TGFb pathway, we undertook a proteomic
approach to identify novel interactors of SMAD7. We stably
integrated a single copy of green fluorescent protein-tagged
SMAD7 into HEK293 cells. From these cells, GFP-immunopre-
cipitates (IPs) were resolved by SDS–PAGE and the interacting
proteins were excised, digested with trypsin and identified by
mass spectrometry. The E3 ubiquitin ligases ITCH, NEDD4,
NEDD4L, SMURF1/2 and WWP1/2, all members of the C2-
WW-HECT family [31], were identified as selective SMAD7
interactors (figure 1a). Of these, SMURF1/2, WWP1 and
NEDD4L have previously been reported to interact with
SMAD7 and modulate the TGFb pathway [7,17,18]. While
the regulation of TGFb signalling by SMAD7-associated E3
ubiquitin ligases has been extensively investigated and
reported, we were drawn to the novel DUB interactors of
SMAD7. USP11 and USP15 were identified as selective interac-
tors of GFP-SMAD7 in three separate experiments. While
USP11 coverage and intensity indicated a robust interaction,
USP15 was less prominent (figure 1a). USP11 and USP15 did
not feature as interactors of GFP-tagged SMADs1–5 in similar
proteomic assays. USP7 and USP9X, the lattera reported deubi-
quitylase for SMAD4 [16], were also identified in the screen.
However, both featured in the control GFP IPs indicating a
non-specific interaction (figure 1a).
3.2. USP11 but not USP15 binds specifically to SMAD7
To confirm the specificity of the USP11–SMAD7 interaction,
SMADs carrying an N-terminal FLAG tag were transiently
transfected into HEK293 cells with or without the N-terminal
HA-tagged USP11. We found that USP11 interacted more
robustly with SMAD7 compared with any of the other
SMAD proteins (figure 1b). FLAG–SMAD7 was also capable
of immunoprecipitating endogenous USP11 (figure 1c).
We also assessed the effect of TGFb (50 pM, 45 min) on the
ability of transfected FLAG–SMAD7 to immunoprecipitate
endogenous USP11. TGFb stimulation did not alter the
SMAD7–USP11 interactions (see the electronic supplemen-
tary material, figure S1). Furthermore, we performed an
endogenous SMAD7 immunoprecipitation and were able to
detect endogenous USP11 in the SMAD7 IPs with or without
TGFb treatment (figure 1d). Despite reports that USP15 inter-
acts with SMADs 2 and 3 [21,32], we failed to detect USP15
interacting with any of the SMAD proteins (see the electronic
supplementary material, figure S2). We performed size-
exclusion chromatography on HaCaT cell extracts in order
to detect potential endogenous USP11 and SMAD7 complex
formation. USP11 and SMAD7 eluted in molecular fractions
much higher than their monomeric weights. They co-elute
in the same high-molecular-weight fractions (fractions
20–21; figure 1e), indicating possible complex formation.
However, both USP11 and SMAD7 also elute in non-
overlapping high-molecular-weight fractions, implying that
they probably also exist in unique complexes with other pro-
teins. TGFb treatment (50 pM, 45 min) did not alter the
elution profile significantly (figure 1e).
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2USP11–SMAD7 interaction and potential complex for-
mation raised two distinct possibilities for USP11 targets
within the TGFb pathway. One, we hypothesized that
USP11 binds and deubiquitylates SMAD7, thereby
inhibiting the TGFb pathway. Two, we hypothesized that
SMAD7 could direct USP11 DUB activity to other pathway
proteins it interacts with, such as the type I TGFb receptors,
thereby enhancing pathway signalling.
3.3. USP11 enhances TGFb pathway signalling
In order to explore the impact of USP11 on the TGFb path-
way, we used HEK293 cells stably expressing GFP or
GFP-USP11 (two to threefold over endogenous USP11) with
or without SMAD7 co-expression. Cells were starved for 4 h
and stimulated with 50 pM TGFb for 1 h. Cell lysates were
resolved by SDS–PAGE. TGFb-induced phospho-SMAD2
levels were slightly enhanced in cells expressing GFP-
USP11 compared with the control cells. This suggested that
SMAD7 is unlikely to be a substrate for USP11. As expected,
SMAD7 expression resulted in significant inhibition of TGFb-
induced phosphorylation of SMAD2, which was partially
rescued by USP11 (figure 2a).
TGFb-induced transcriptional responses require phospho-
SMAD2/3 translocate to the nucleus [33,34]. We therefore
fractionated transiently transfected HEK293 cells into nuclear
and cytoplasmic fractions. We found increased phospho-
SMAD2 levels within the nuclear fractions in response to
TGFbandthiswasfurtherenhancedbyUSP11over-expression
(figure 2b). The TGFb-induced phospho-SMAD2 levels in
the cytoplasmic fractions also increased with USP11 over-
expression. Additionally, nuclear phospho-SMAD2 was
enhanced by USP11 over-expression even in the absence of
TGFb stimulation (figure 2b). To confirm the transcriptional
effect of over-expressed USP11, we transfected cells with a
SMAD3-dependent TGFb-responsive luciferase construct
[35,36]. Consistent with the enhanced phospho-SMAD2
levels, USP11 significantly enhanced the TGFb-induced repor-
ter activity. Furthermore, USP11 was able to partially rescue
the over-riding inhibitory effect of SMAD7 over-expression
on TGFb-induced transcriptional reporter activity (figure 2c).
We repeated the TGFb-responsive transcriptional reporter
assay with a catalytically inactive mutant of USP11 (C318S)
[25]. While wild-type (wt) USP11 significantly enhanced
TGFb-induced transcriptional reporter activity, the catalyti-
cally inactive mutant USP11 (C318S) had no effect (see
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Figure 1. Identification and characterization of USP11 as an interactor of SMAD7. (a) Representative Coomassie-stained gels showing anti-GFP IPs from HEK293
extracts expressing GFP-alone or GFP-SMAD7. The interacting proteins were excised as 2 mm gel pieces, digested with trypsin and identified by mass spectrometry.
The gel piece from which USP11 was identified is indicated. A summary table of various Smad-interacting E3 ubiquitin ligases and DUBs identified by mass
spectrometry is included. The sequence coverage of USP11 and USP15 in GFP-SMAD7 IPs is indicated. (b) HEK293 cells were co-transfected transiently with
HA-USP11 and FLAG–SMADs. FLAG IPs and lysate inputs were immunoblotted with FLAG and HA antibodies as indicated. (c) HEK293 cells were transiently
transfected with FLAG–SMADs only. FLAG IPs and lysate inputs were immunoblotted with FLAG and endogenous USP11 antibodies. (d) Lysates from HEK293 cells
treated with vehicle or TGFb (50 pM 45 min) were immunoprecipitated using pre-immune IgG or a SMAD7 antibody covalently bound to Dynabeads (Invitrogen).
IPs and lysate inputs were immunoblotted with endogenous USP11, SMAD7 and phospho-SMAD2 antibodies. (e) Extracts from HaCaT cells starved for 4 h and
stimulated with or without 50 pM TGFb for 1 h were separated by size-exclusion gel chromatography. The collected fractions were immunoblotted with anti-USP11
and anti-SMAD7 antibodies.
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3figure 2d and the electronic supplementary material, figure S3).
This indicates that USP11 DUB activity is required to exert its
effect on the TGFb pathway. To determine the specificity of
USP11 on TGFb-induced transcriptional reporter activity, we
tested USP5 in the same assay. While being a member of the
USP family of deubiquitylases (DUBs), it did not appear in
SMAD7 IPs in the proteomic screens. We found USP5 had no
effect on TGFb-induced reporter activity (figure 2d), implying
selective effects of USP11 on the TGFb pathway.
3.4. USP11 knockdown inhibits TGFb
pathway signalling
Next, we investigated the impact of RNAi-mediated depletion
of USP11 on TGFb signalling. Two distinct pools of siRNAs
targeting USP11 yielded a moderate reduction (60–80%) in
endogenous USP11 expression, while a control siRNA target-
ing FoxO4 [37] did not (figure 3). Depletion of USP11 by
these RNAi target sequences resulted in a reduction in
levels of TGFb-induced phospho-SMAD2 and 3 without
affecting total SMAD2/3 levels (figure 3a,b). Consistent
with these observations, RNAi-mediated depletion of USP11
resulted in the reduced expression of TGFb-target genes
PAI-1, and GADD45B (figure 3c). We also confirmed that
USP11 RNAi did not target USP15 and vice versa, confirming
that the observed effects of USP11 on the TGFb pathway are
likely to be due to USP11 (see the electronic supplementary
material, figure S4).
The preceding results clearly show that USP11 affects
SMAD2/3 phosphorylation; therefore, it would appear that
USP11 modulates the pathway upstream of SMAD2/3 tran-
scriptional activity. USP11 activity antagonized SMAD7
pathway inhibition, therefore SMAD7 was an unlikely
USP11 substrate. Additionally, endogenous USP11 was not
able to interact with any other SMADs besides SMAD7.
Finally, SMAD7 is known for targeting the TGFb R1 receptor
(ALK5) for ubiquitylation by E3 ligases [7]. We therefore
hypothesized that USP11 directed by SMAD7 plays a role
in balancing receptor ubiquitylation.
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Figure 2. USP11 enhances TGFb pathway signalling. (a) HEK293 cells stably expressing GFP or GFP-USP11 were transfected with HA empty vector or HA-SMAD7,
starved for 4 h and stimulated with 50 pM TGFb for 1 h prior to lysis. Extracts were resolved by SDS–PAGE and immunoblotted with antibodies against GFP-USP11,
HA-SMAD7, endogenous phospho-SMAD2 and SMAD2. (b) HEK293 cells transiently transfected with or without HA-USP11 were starved for 4 h and stimulated with
50 pM TGFb for 1 h prior to separation into cytoplasmic and nuclear fractions. The fractions were resolved by SDS–PAGE and immunoblotted with antibodies
against HA-USP11, lamin, GAPDH, endogenous phospho-SMAD2 and SMAD2. All immunoblots are representative of at least three biological replicates. (c) TGFb
transcriptional reporter activity (using a SMAD responsive element (SRE) luciferase reporter assay) normalized to renilla-luciferase in HEK293 cells transiently
transfected with SRE-luciferase, renilla-luciferase, HA-USP11, FLAG–SMAD7 and stimulated for 6 h with or without 50 pM TGFb, as indicated. Results are average of
five biological replicates. Asterisk denotes statistical significance over vector transfected and unstimulated cells. (d) TGFb transcriptional reporter activity (using an
SRE luciferase reporter assay) normalized to renilla-luciferase in HEK293 cells transiently transfected with SRE-luciferase, renilla-luciferase, HA-USP11, HA-C318S
USP11 (DD), HA-USP5 and stimulated for 6 h with or without 50 pM TGFb, as indicated. Results are average of three biological replicates. Asterisk denotes statistical
significance over vector transfected and unstimulated cells. Plus symbols denote positive divergence, minus symbols denote negative divergence.
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43.5. USP11 interacts with ALK5
HEK293cellsweretransientlytransfectedwithFLAG-ALK5and
HA-USP11 in the presence or absence of HA-SMAD7. FLAG-
ALK5 interacted with HA-USP11, and this interaction was only
slightly enhanced in the presence of over-expressed SMAD7
(figure4a). Furthermore, FLAG-ALK5wasalsoabletoimmuno-
precipitate endogenous USP11; however, over-expressing
SMAD7 did not enhance the interaction between FLAG-ALK5
and endogenous USP11 (figure 4b). We also performed an
endogenous ALK5 immunoprecipitation and were able to show
endogenousUSP11intheALK5IPs.Theredidseemtobeaslight
enhancement of the interaction with TGFbtreatment (figure 4c).
In ALK5 IPs, in addition to the predicted molecular weight
bands, the ALK5 antibody also recognized high-molecular-
weight cross-reacting bands. We therefore verified the loss of
native molecular weight ALK5 in the flow-through extracts
following ALK5 immunoprecipitation (figure 4c).
In light of the USP11–ALK5 interaction, we characterized
the subcellular localization of endogenous SMAD7, USP11
and ALK5toconfirmthat their interactionswerenot an artefact
of the biochemical techniques used. We performed fixed-cell
immunofluorescence on HaCaT keratinocyte cells and found
USP11 to be both cytoplasmic and nuclear (see the electronic
supplementary material, figure S5, top left panel). USP11
antibody specificity was confirmed using fixed-cell
immunofluorescence in the presence or absence of USP11
knockdown using siRNA intwodifferent cell lines (seetheelec-
tronic supplementary material, figure S6). Consistent with
previous reports, SMAD7 was observed mostly in the cyto-
plasm (see the electronic supplementary material, figure S5,
middle left panel) [38,39]. Endogenous ALK5 was found
mainly in the cytoplasm, as described in previous reports (see
the electronic supplementary material, figure S5, bottom left
panel) [40,41]. We demonstrated significant overlap between
USP11 and SMAD7 in the cytoplasm (see the electronic sup-
plementary material, figure S5, top right panel). We also
demonstrate a considerable overlap of USP11 and ALK5 (see
the electronic supplementary material, figure S5, middle right
panel). As expected, ALK5 and SMAD7 overlap was seen in
both the membrane and cytoplasm, consistent with reports
of receptor internalization for both pathway signalling and
receptor degradation [42].
3.6. USP11 deubiquitylates ALK5
Multiple TGFb pathway members are ubiquitylated and could
be potential deubiquitylation targets [11–13,17,18]. However,
because USP11 interacts with ALK5 and positively regulates
the TGFb pathway dependent on its catalytic activity, ALK5
appeared to be a strong candidate for deubiquitylation by
USP11. When over-expressed in HEK293 cells, FLAG-ALK5
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Figure 3. RNAi depletion of USP11 inhibits TGFb pathway signalling. (a) HEK293 cells were transiently transfected with siRNA targeting FoxO4 as control or USP11,
starved for 4 h and stimulated with 50 pM TGFb for 1 h prior to lysis. Extracts were resolved by SDS–PAGE and immunoblotted with antibodies against
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(c) HEK293 cells were transiently transfected with siRNA targeting FoxO4 as control or USP11, starved overnight and stimulated for 4 h with 50 pM TGFb. The
expression of TGFb-target genes PAI1 and GADD45B as well as USP11 knockdown were assessed by semiquantitative RT-PCR. Results are average of three biological
replicates. Asterisk denotes statistical significance.
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5is polyubiquitylated. Over-expressed wt USP11 was able to
deubiquitylate ALK5. Catalytically inactive USP11 (C318S)
could not (figure 5a), despite its ability to bind ALK5 (see the
electronic supplementary material, figure S7). Over-expression
of SMAD7 further increased ALK5 ubiquitylation, particularly
K48-linked ubiquitin chains known to target proteins for pro-
teasomal degradation. USP11 was able to reduce ALK5
polyubiquitylation, although not to basal levels. This denoted
a receptor ubiquitylation balance between USP11 and
SMAD7-bound E3 ligases (figure 5b). If USP11 does enhance
pathway signalling through ALK5 deubiquitylation, then inhi-
biting the proteasome would negate any USP11 modulation.
Consistent with this, we were able to show that the decrease
in TGFb-induced SMAD2 phosphorylation by USP11
depletion is abrogated by proteasomal inhibition (20 mM
MG132, 3 h before TGFb stimulation). We also see an increase
in high-molecular-weight ALK5 bands both with USP11
depletion and MG132 treatment separately, but no further
enhancement of these high-molecular-weight bands with
MG132 and USP11 depletion together. As expected MG132
treatment increased general polyubiquitylation levels (figure
5c). This result indicates a central role for the proteasome in
USP11 modulation of TGFb pathway signalling.
3.7. USP11 knockdown inhibits epithelial to
mesenchymal transition
Epithelial to mesenchymal transition (EMT) is a process,
whereby epithelial cells undergo profound changes in
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Figure 4. USP11 interacts with ALK5. (a) HEK293 cells were transiently transfected with FLAG-ALK5, HA-USP11 and/or HA-SMAD7, as indicated. Extracts or FLAG IPs
were resolved by SDS–PAGE and immunoblotted with antibodies against HA-USP11, HA-SMAD7 and ALK5. (b) HEK293 cells were transiently transfected with
3XFLAG-ALK5, and HA-SMAD7, as indicated. Extracts or FLAG IPs were resolved by SDS–PAGE and immunoblotted with antibodies against endogenous USP11,
HA-SMAD7 and 3XFLAG-ALK5. All immunoblots are representative of at least three biological replicates. (c) Lysates from HEK293 cells treated with vehicle or TGFb
(50 pM 45 min) were immunoprecipitated using pre-immune IgG or an ALK5 antibody covalently bound to Dynabeads. IPs, flow-through extracts and lysate inputs
were immunoblotted with endogenous USP11, ALK5 and phospho-SMAD2 antibodies. The arrowhead denotes the native molecular weight ALK5.
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6shape and behaviour to become mesenchymal cells. EMT is a
fundamental process during embryogenesis and organo-
genesis. The acquisition of the mesenchymal phenotype
characterized by the loss of E-cadherin-mediated cell–cell
adhesion and loss of apical basal cell polarity among others
result in enhanced cellular plasticity. While the precise roles
of EMT in cancer progression are still unclear, EMT may
confer malignant traits such as motility, stemness, invasive-
ness and survival in cancer cells. EMT is also thought to
play an important role in fibrosis. TGFb is a potent inducer
of EMT [43–45]. Given the impact of USP11 on the TGFb
pathway, we investigated whether USP11 was capable of
altering TGFb-induced EMT in NMuMG cells, a mouse
mammary epithelial cell line. TGFb treatment (75 pM for
24 h) of control FoxO4 siRNA transfected cells displayed a
robust EMT response. Cells with RNAi-mediated depletion
of USP11 showed a reduction in EMT induction after 24 h
of 75 pM TGFb stimulation, mimicking the effects of
TGFb inhibitor SB505124 (figure 6a,b) [46]. These effects
were seen using immunofluorescence; E-cadherin, an epi-
thelial marker, is clearly membranous in untreated control
cells, while it disappears from the membrane with TGFb
treatment. Membrane E-cadherin persisted in both USP11-
depleted and SB505124-treated cells despite TGFb treatment.
Fibronectin, a mesenchymal marker, was increased in the
TGFb-treated control cells as seen by immunofluorescence.
In contrast, little or no increase was seen in the USP11-
depleted and the SB505124-treated cells (figure 6a). Using
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Figure 5. USP11 deubiquitylates ALK5. (a) HEK293 cells were trasfected with FLAG-ALK5 with or without a wt or catalytically inactive mutant (C318S) of HA-USP11.
The FLAG-ALK5 IPs and extracts were resolved by SDS–PAGE and immunoblotted with antibodies against ubiquitin, FLAG-ALK5 and HA-USP11. (b) HEK293
cells were trasfected with FLAG-ALK5 with or without HA-USP11 or GFP-SMAD7, as indicated. The FLAG-ALK5 IPs and extracts were resolved by SDS–PAGE
and immunoblotted with antibodies against ubiquitin, K48-linked polyubiquitin chain, FLAG-ALK5, GFP-SMAD7 and HA-USP11. (c) HEK293 cells were trasfected
with FLAG-ALK5 with FoxO4 as control or USP11 siRNA, and treated with or without MG132 and/or TGFb, as indicated. Extracts were resolved by SDS–PAGE
and immunoblotted with antibodies against USP11, phospho-SMAD2, SMAD2, ALK5 and ubiquitin. All immunoblots are representative of at least three
biological replicates.
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7phase contrast microscopy, it was found that TGFb-treated
control cells show a morphological shift from cuboidal (epi-
thelial) to elongated (mesenchymal). SB505124-treated cells
showed no morphological changes, while the USP11-
depleted cells were a mix of mostly epithelial and some
mesenchymal reflecting the transfection efficiency of USP11
siRNA. Western blotting of extracts of the same pictured
cells shows a blunted TGFb-induced reduction of E-cadherin
upon USP11 depletion. Complete inhibition of the TGFb
pathway using 1 mM SB505124, added to cells 2 h prior to
TGFb treatment, had a similar but stronger effect (figure
6b). Clearly, RNAi-mediated USP11 depletion by multiple
siRNAs in both mouse and human cells show the same inhibi-
tory effects on TGFb-induced phosphorylation of SMAD2 as
well as EMT. This implies that these consequences are unli-
kely to be due to the off target effects of the siRNAs used
and also highlights the global effects of USP11 across species.
4. Discussion
Despite a plethora of reports on TGFb signalling regulation
by E3-ubiquitin ligases, the DUBs that reverse or edit the
effects of these E3-ubiquitin ligases have not received much
TGFb
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Figure 6. USP11 knockdown inhibits epithelial to mesenchymal transition. NMuMG cells were transiently transfected with siRNA targeting mouse FoxO4 as control
or USP11 before being treated with 75 pM TGFb for 24 h in the presence or absence of 1 mM TGFb inhibitor SB505124. (a) E-cadherin and fibronectin
immunofluorescence after TGFb treatment (b) light microscopy of cells after TGFb treatment. Western blotting of extracts from cells pictured were resolved on
SDS–PAGE gels and blotted for USP11 (the arrowhead denotes USP11; a non-specific band appeared below USP11 in mouse cell extracts that was not present in
human cell extracts), phospho-SMAD2, SMAD2 and E-cadherin.
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8scrutiny. To date, very few TGFb pathway DUB regulators
have been identified [11]. Here, we identify and characterize
a new TGFb pathway DUB: USP11.
We identified USP11 from a proteomic approach as an
interactor of the inhibitory SMAD7 and further confirmed
this interaction using a biochemical approach. Size-exclusion
chromatography also alluded to the possibility of potential
complex formation between USP11 and SMAD7. Despite its
interaction with SMAD7, we found that USP11 enhanced
TGFb signalling and bound the TGFb R1 receptor (ALK5).
Pathway signalling was modulated through changes in
SMAD2/3 phosphorylation. SMAD nuclear translocation
and changes in transcriptional responses were also affected
by USP11. Furthermore, we show that only wt USP11 is
capable of eliciting and enhancing the R-SMAD transcrip-
tional responses. By contrast, a catalytically inactive USP11
(C318S), still capable of binding ALK5, could not elicit the
same response. Neither could the related DUB USP5. There-
fore, the USP11 effects we observe on TGFb signalling are
specific and dependent on USP11 DUB activity. While
USP15 was found as a potential SMAD7 interactor in our pro-
teomic screens, subsequent biochemical approaches failed to
show an interaction with any of the SMAD proteins.
We initially investigated SMAD7 as a potential target for
USP11 deubiquitylation. However, USP11 enhancement of
pathway signalling, among other results, was at odds with
this target. ALK5 was the more logical target of USP11 de-
ubiquitylation. USP11 was in fact capable of reducing
receptor ubiquitylation when over-expressed, whereas the
catalytically inactive USP11 was not. The reverse effects
were seen with reduced USP11 expression using RNAi. The
proteasomal inhibitor MG132 negated the effect of USP11
knockdown on both ubiquitylation and SMAD phosphoryl-
ation indicating a central role for proteasomal degradation
in USP11–TGFb pathway modulation.
SMAD7, a transcriptional target of TGFb signalling, tar-
gets the active receptors for degradation by bringing E3
ligases (SMURF1/2 and WWP1) to ubiquitylate the receptor
[17,18]. Depending on the relative activities of the E3 ligase
and USP11, both bound to SMAD7, a balance between ubiqui-
tylation and deubiquitylation could therefore decide receptor
fate.ASMAD7-E3complex targetingthereceptor for ubiquity-
lation would lead to receptor degradation and signalling
termination. Conversely, a SMAD7-USP11 complex would
deubiquitylate the receptor, preventing its degradation and
allow continued signalling (figure 7). This explanation would
fit well with the experimental dataset we have achieved thus
far. Furthermore, other BMP and TGFb pathway receptors
could also be involved in this ubiquitylation balance and
therefore potential modulation targets for USP11.
A second mode of action that may not depend on the
DUB activity of USP11, but its ability to bind and sequester
SMAD7, could also be possible. This of course would also
depend on the relative abundance of USP11 compared with
SMAD7 and the stoichiometry of the interaction between
them. However, this would be a complementary mechanism,
because without its DUB activity, over-expressed USP11
(C318S) was not able to elicit or enhance a transcriptional
response upon TGFb stimulation. A third mode of action
we feel is safe to disregard. USP11 may bind ALK5 and pre-
vent the SMAD7-E3 ligase complex access to ubiquitylate the
receptor. However, one would expect over-expression of
the catalytically inactive USP11 that does bind to the receptor
would provide such protection. Quite the opposite, it did not
inhibit receptor ubiquitylation levels, they actually increased
slightly (figure 5a). While the second mode of action needs to
be further studied, it cannot fit within the scope of this paper.
The study would need to take into account the intracellular
movement of USP11 and SMAD7 and the stoichiometry of
the interactions, both requiring extensive experimentation.
Receptor movement and internalization should also be taken
into account to complete the picture, as we cannot assume
the receptor is stationary at the cell surface. While preliminary
data for the second mechanism of action are promising, these
have opened a much wider avenue of study than we intended
to address with this paper.
Finally, we investigated whether USP11 was capable of
modulating a TGFb-induced EMT. EMT is a core feature
USP11
E
3
R-SMAD R-SMAD P
SMAD4
R-SMAD P SMAD4
DNA-binding
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co-repressors
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SMAD7
P
degradation
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Figure 7. A schematic representation of the TGFb pathway regulation by USP11. USP11 augments TGFb signalling by deubiquitylating the type I TGFb receptor,
thereby counterbalancing the negative effect E3 ubiquitin ligases and SMAD7 have on the receptors.
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9of TGFb pathway functions both in embryonic development
and tumorigenesis. We found reduction of USP11 expression
inhibited the pathway similar to TGFb pathway blockade
using a small molecule inhibitor. Both were able to reduce
the EMT. This was particularly exciting, as modulating
USP11 itself may open new avenues of anti-cancer drug dis-
covery. While we chose EMT as a physiological readout of
pathway modulation, other TGFb-dependent physiological
effects would also need to be taken into account during
drug discovery especially where the TGFb pathway acts
both as a tumour promoter and suppressor. Modulating
USP11 function within the TGFb pathway would therefore
provide a two-way level of control depending on the cellular
context. It should be cautioned that directly targeting USP11
would have consequences beyond the TGFb pathway as it
has multiple reported targets in other pathways. Therefore,
drug discovery should be concentrated on interfering with
adaptor proteins that direct USP11 to certain parts of the
target pathway, such as SMAD7 reported here for the TGFb
pathway. One should also consider that USP11 itself may be
further modulated, not only by its adaptor proteins, but
by post-translational modifications further increasing the
potential ways to interfere with unwanted pathway signalling.
5. Material and methods
5.1. Materials
Cell culture media and antibiotics were purchased from
Gibco. Foetal bovine serum (FBS) was from Hyclone. Poly-
ethyleneimine (PEI) was from Polysciences (no. 24765).
Lipofectamine 2000 was from Invitrogen (no. 52887). Trans-
fectin was from Bio-Rad (no. 170-3551). Recombinant
human TGFb1 was from R&D (no. 240-B-002). Complete pro-
tease inhibitor cocktail-EDTA free was from Roche (no.
1187380001). RNA extraction kit was from Macherey-Nagel
(no. 740955). Coomassie protein assay reagent was from
Thermo Scientific (no. 1856209). Spin-X columns were from
Costar (no. 8163). Chromatography columns were from Bio-
Rad (no. 731-1550). GFP-Trap-A beads were from Chromatek
(no. gta-20). Anti-FLAG M2 affinity gel was from Sigma
(A2220). Glutathione sepharose beads were from GE health-
care (no. 17-0756-05). Protein G Dynabeads were from
Invitrogen (no. 100.04D). NuPAGE 10 per cent bis–tris gels
were from Invitrogen. Acrylamide was from Flowgen Bio-
science (no. H16984). BS
3 cross-linking reagent was from
Thermo Scientific (no. 21585). Colloidal blue staining kit was
from Invitrogen (no. LC6025). Nitrocellulose membranes
were from Whatman (no. 10401191). Enhanced chemilumines-
cence (ECL) reagents were from Thermo Scientific (no. 34080).
Western blot stripping buffer was from Thermo Scientific (no.
46430). Labtek chamber slides were from Nalge Nunc Int.
(no. 154941). Glass bottom dishes were from WillCo (GWSt-
3522). Vectashield mounting solution with DAPI was from
Vectorlabs (no. H-1500). Antibodies to detect USP11 and
USP15 were generated by injecting full-length GST-USP11/
15 into sheep and affinity purified. FLAG-HRPand fibronectin
antibodieswerefromSigma(nosA8592,F3648).HA-HRPanti-
body was from Roche (no. 12013819001). SMAD7 antibody
was from R&D (no. MAB2029). TGFbR1 antibody was from
Santa Cruz Biotechnology (no. sc-398). Phospho-SMAD2
Ser465/467 antibody, SMAD2/3, GAPDH, E-cadherin and
Lamin A/C were from Cell Signaling Technology (nos 3101,
3102, 2118, 4065, 2032, respectively). Ubiquitin antibody was
fromDako(no.Z0458).Phospho-SMAD3Ser423/425antibody
was from Rockland Inc. (no. 601-401-919). Goat anti-rabbit,
mouse and sheep HRP-conjugated antibodies were from
Pierce (nos 31460, 31430, 31480), respectively. Alexa Fluor
488 anti-sheep, 594 anti-mouse and 647 anti-rabbit were
from Invitrogen (nos A11015, A11005, A31573, respectively).
Nuclear cytoplasmic extraction reagents were from Thermo
Scientific (no. 7883). Dual luciferase reporter assay kit was
from Promega (no. E1960). RNA extraction kit was from
Qiagen (no. 74004). iScript cDNA synthesis kit was from Bio-
Rad (no. 170-8891). 2X SYBR Green Master was from Quanta
Biosciences (no. 95071).
5.2. Plasmids
Mammalian expression constructs expressing human USP11,
ALK5, SMAD1, 2, 3, 4 and 7 were cloned into pCMV5 or
pCDNA-Frt-TO (Invitrogen) vectors with N-terminal FLAG,
HA or GFP-tags. pCDNA-Frt-TO plasmids were used to gen-
erate stable HEK293 cell lines following manufacturers’
protocol (Invitrogen). pGL4.11 LUC2p-SRE (SMAD-response
element) reporter constructs were generated based on four
repeats of the Smad-binding element (GTCTAG(N)C), as
described previously [35,36]. Renilla-luciferase reporter was
used as transfection control. All DNA constructs used were
verified by DNA sequencing, performed by DNA Sequencing
Service (MRCPPU, College of Life Sciences, University of
Dundee, Scotland, www.dnaseq.co.uk) using Applied
Biosystems Big-Dye Ver 3.1 chemistry on an Applied
Biosystems model 3730 automated capillary DNA sequencer.
5.3. Cell culture, transfection and lysis
Cells were propagated in DMEM supplemented with 10 per
cent FBS, 1 per cent penicillin/streptomycin and 2 mM
L-glutamine. A 5 mgm l
21 insulin was added to the above
media when propagating NMuMG cells. Cells were kept at
378C in a humidified incubator with 5 per cent CO2.C e l ll i n e s
stably expressing tetracycline-inducible GFP-USP11 were
growninmediathatadditionallycontained100 mgm l
21hygro-
mycin and 15 mgm l
21 blasticidin. Human embryonic kidney
(HEK293) cells were transfected using PEI, as described pre-
viously [47]. Human keratinocyte (HaCaT) and HEK293 cells
were transfected using Lipofectamine 2000 or Transfectin
according to manufacturers’ protocol. Cells were seeded and
transfected at 60 per cent confluency. They were allowed 48 h
of growth in full growth medium before being treated
with appropriate ligands and harvested. For protein appli-
cations, cells were scraped directly into cell lysis buffer
(50 mM Tris–HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1%
Triton X-100, 1 mM activated sodium orthovanadate, 50 mM
sodiumfluoride,5 mMsodiumpyrophosphate,0.27 Msucrose,
5m Mb-glycerophosphate, 0.1% b-mercaptoethanol and one
tablet of protease inhibitor cocktail per 25 ml) and snap-
frozen in liquid nitrogen. For RNA applications, cells were
processed using an RNA extraction kit (Qiagen) according to
manufacturers’ instructions. For luciferase assays (Promega),
cells were prepared according to the manufacturers’ protocol
and assayed on a MicroLumat plus LB 96V luminometer from
Berthold technologies.
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105.4. Mass-spectrometric analysis
Mass-spectrometric analysis was performed by LC–MS–MS
using a linear ion trap-orbitrap hybrid mass spectrometer
(LTQ-Orbitrap, Thermo Fisher Scientific) equipped with a
nanoelectrospray ion source (Thermo) and coupled to a Prox-
eon EASY-nLC system. Peptides were typically injected onto
a Dionex Acclaim PepMap100 reverse phase C18 3 mm
column, 75 mm   15 cm (no. 160321), with a flow of
300 nl min
21 and eluted with a 40 min linear gradient of 95
per cent solvent A (2% acetonitrile, 0.1% formic acid in
H2O) to 50 per cent solvent B (90% acetonitrile, 0.08%
formic acid in H2O). The instrument was operated with the
‘lock mass’ option to improve the mass accuracy of precursor
ions and data were acquired in the data-dependent mode,
automatically switching between MS and MS–MS acqui-
sition. Full scan spectra (m/z 340–1800) were acquired in
the orbitrap with resolution R ¼ 60000 at m/z 400 (after
accumulation to a target value of 1000 000). The five most
intense ions, above a specified minimum signal threshold of
20000, based upon a low resolution (R ¼ 15000) preview of
the survey scan, were fragmented by collision-induced dis-
sociation and recorded in the linear ion trap (target value of
30000). Data were analysed by searching the SwissProt/
Human database using the Mascot search algorithm
(http://www.matrixscience.com).
5.5. Immunoprecipitation
Snap-frozen cells were allowed to thaw on ice and centri-
fuged at 17 900g for 10 min at 48C. Protein concentration
was determined spectrophotometrically. Lysates (500 mg)
were then immunoprecipitated using 10 ml packed beads
(GFP-Trap, or FLAG) rotating for 2 h at 48C. Protein-bound
beads were then washed twice in lysis buffer with 0.5 M
NaCl, and twice in buffer A (50 mM Tris–HCl pH 7.5,
0.1 mM EGTA, 0.1% b-mercaptoethanol) at 48C. Samples
were then reduced in 1  sample buffer (50 mM Tris–HCl
pH 6.8, 2% SDS, 10% glycerol, 0.02% bromophenol blue,
0.1% b-mercaptoethanol), boiled at 958C for 5 min prior to
resolving by SDS–PAGE. For endogenous IPs, 5 mg of
protein lysates was immunoprecipitated with 50 ml protein
G dynabeads covalently bound to 5 mg SMAD7 or ALK5
antibody for 30 min at room temperature. Covalent binding
was performed by using BS
3 cross-linking reagent following
manufacturers’ protocol. Protein-bound beads were then
washed thrice in phosphate-buffered saline (PBS), resus-
pended in 100 ml of PBS and transferred to a new tube. PBS
was replaced with 50 ml1   NuPAGE LDS buffer with 1
per cent b-mercaptoethanol. Samples were heated for
10 min at 708C to elute the proteins prior to resolving by
SDS–PAGE.
5.6. Gel filtration chromatography
HaCaT cells were lysed and filtered through Spin-X columns.
A 1 mg of cleared protein extract was subjected to separation
through a Superose 6 10/300 GL Column (GE Health Care),
which was equilibrated, as described previously [48]. Eluting
fractions (32   0.5 ml) were collected and processed for
SDS–PAGE, as described earlier.
5.7. Immunoblotting
Snap-frozen cells were allowed to thaw on ice and centrifuged
at 17900g for 10 min at 48C. Protein concentration was deter-
mined spectrophotometrically. Lysates (25 mg) or IPs were
reduced in sample buffer and separated using 10 per cent
denaturing gels and transferred onto a nitrocellulose mem-
brane. Membranes were blocked with 5 per cent non-fat dry
milk in Tris-buffered saline (50mM Tris, 150mM NaCl) con-
taining 0.2 per cent Tween-20 (TBST), incubated overnight at
48C with primary antibody, followed by incubation with
horseradish peroxidase (HRP)-conjugated secondary antibody
(1:5000). Detection was performed using ECL reagents.
5.8. Immunofluorescence
Cells seeded on Labtek chamber slides for fixed-cell immuno-
fluoresence were allowed to grow for 24 h. Cells were fixed in
4 per cent paraformaldehyde for 20 min and permeabilized
with 0.2 per cent Triton-X100 in PBS for 10 min at room temp-
erature. Permeabilized cells were then incubated for 1 h at
room temperature with blocking solution (5% donkey serum
in PBS). Primary antibodies were added in blocking solution
and incubated overnight at 48C. Secondary fluor-conjugated
antibodies were added after multiple washes in PBS for
90 min in the dark at room temperature. Alexa Fluor 488 nm
anti-sheep (green), 594 nm anti-mouse (red) and 647 nm anti-
rabbit (far red) were used. Vectashield mounting medium
with DAPIwasthenused.Images were analysed using aDelta-
vision core restoration microscope (Applied Precision, USA).
5.9. RNAi and quantitative PCR
The siRNA and qPCR primer sequences used in this study
are as follows:
Human siRNAs against USP11: iUSP11-1 (50–30): GAUU-
CUAUUGGCCUAGUAU; iUSP11-2: CAGAGAUGAAGAA
GCGUUA; iUSP11-3 GUCAUAGAGCUGCCCAACA were
from Sigma. Smartpool siRNA GGGCAAAUCUCACACU
GUU; GAACAAGGUUGGCCAUUU; GAUGAUAUCUUCG
UCUAUG;GAGAAGCACUGGUAUAAGCwasfromThermo.
Human siRNAs against USP15: iUSP15-1 (50–30): CUCUU
GAGAAUGUGCCGAU; iUSP15-2: CACAAUAGAUACAA
UUGAA; iUSP15–3 CACAUUGAUGGAAGGUCAA were
from Sigma.
Human esiRNA USP11 target sequence:
GGCATCTCAGGGAGAGACTGCTAGAAGGAGATGAT
TATGTGCTGCTCCCAGCGCCCTGCTTGGAACTACATGG
TCAGCTGGTATGGCTTAATGGATGGCCAGCCACCTATT-
GAGCGCAAGGTAATAGAACTTCCTGGCATTCGGAAGG
TGGAAGTGTACCCACTAGAGCTACTGCTCGTTCAGCAC
AGTGATATGGAAACAGCTCTCACCATTCAGTTTAGCTA
TACTGATTCTGTGGAACTAGTCTTGCAAACAGCTCGGG
AGCAGTTTCTGGTAGAGCCTCAGGAAGACACGCGCCT
CTGGACCAAGAACTCAGAGGGCTCTTTGGATCGACTGT
GTAATACACAGATCACGCTGCTTGATGCCTGCCTTGAG
ACTGGGCAGTTGGTCATCATGGAGACTCGAAACAAAG
ATGGCACTTGGCC
Mouse siRNAs against USP11: CUGUGAUCGUGGACA
CUUU; CCUACUAUGGUCUGAUACU; CAAAUAUGAUC
UCAUCGCA were from Sigma.
qPCR primers used were:
GAPDH (F,R) (ATCTTCTTTTGCGTCGCCAG, GCTGA
GACACCATGGGGAA)
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11FoxO4 (F,R) (TTGGAGAACCTGGAGTATGTGACA, AA
GCTTCCAGGCATGACTCAG)
GADD45B (F,R)(AGTCGGCCAAGTTGATGAAT, CCTC
CTCCTCCTCGTCAAT)
PAI-1 (F,R) (AGCTCCTTGTACAGATGCCG, ACAACAG
GAGGAGAAACCCA)
SMAD7 (F,R) (CTGTGCAAAGTGTTCAGGTG, TTGAG
AAAATCCATCGGGTA)
USP11 (F,R) (GTGTTCAAGAACAAGGTTGG, CGATTA
AGGTCCTCATGCAG).
qPCR reactions were performed in triplicate on an iQ5 PCR
machine (Bio-Rad) and data analysed using Microsoft EXCEL.
5.10. Statistical analysis
All experiments have a minimum n ¼ 3. Error bars represent
the standard deviation. Statistical comparisons (p-values)
were obtained from Wilcoxon rank-sum tests.
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